Background: Phyllodes tumors (PTs) of the breast are rare biphasic neoplasms and are classified as benign, borderline, or malignant. Many biological markers have been studied to discriminate between different grades of PTs. IMP3 is a member of the insulin-like growth factor II mRNA binding protein (IMP) family and is expressed in developing tissues during embryogenesis, whereas in adult tissues it is found only at low or undetectable levels. IMP3 is considered a marker of biological aggressiveness in many cancers, including breast and lung. The aim of this study was to evaluate the immunohistochemical expression of IMP3 in a series of PTs and to determine its association with histological grade and clinical outcome.
Materials And Methods: We reviewed retrospectively 62 cases of PTs including their recurrences and 20 cases of fibroadenoma. PTs have been classified as benign in 40 cases, borderline in 13 cases, and malignant in 9 cases.
Results: There were significant differences in IMP3 expression: in malignant PTs IMP3 expression was higher (56% of cases) than in borderline (15%) and benign cases (5%), (P = .001). Fibroadenoma showed no expression for IMP3. IMP3 expression was different in cases with recurrence than cases without recurrence. Furthermore, 3 of the recurrences had a higher histological grade with a positive IMP3 expression compared with the primary tumor.
Conclusions: This is the first study evaluating the IMP3 immunohistochemical expression in PTs. Its expression correlates with histological grade and could be used in the differential diagnosis of fibroepithelial tumors and in predicting a more aggressive behavior.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1066896915603119 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review.
Diagnostics (Basel)
December 2024
Orthopedic Surgery, Macquarie University Hospital, Sydney, NSW 2113, Australia.
: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers.
View Article and Find Full Text PDFExploring the Regulatory Interaction of Differentially Expressed Proteins in Cleft Palate Induced by Retinoic Acid.
Protein Pept Lett
October 2024
Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, China.
Objective: This study aimed to identify novel proteins involved in retinoic acid (RA)-induced embryonic cleft palate development.
Method: The palate tissues of the control and RA-treated E14.5 were dissected and subjected to iTRAQ-based proteomic analysis.
IMP3, CDK4, MDM2 and β-catenin expression in Enchondroma and Central Chondrosarcoma: Diagnostic and prognostic utility.
Clinics (Sao Paulo)
October 2024
Department of Pathology, Universidade Estatual de Campinas (Unicamp), Campinas, SP, Brazil.
Introduction: The role of IMP3, CDK4, MDM2 and β-catenin proteins in Enchondroma and Central Chondrosarcoma is not totally understood. The aim of this study is to evaluate the immunoexpression of these proteins, associating histological grade, clinical data and prognosis to these tumors.
Methods: This is a retrospective-analytical study of 32 Enchondroma and 70 Central Chondrosarcoma.
Prognostic Value of IMP3 Expression in Squamous Cervical Cancer.
Appl Immunohistochem Mol Morphol
October 2024
Department of Gynecology and obstretics, University Hospital Mostar.
Cervical cancer remains one of the leading causes of death from malignant diseases in women worldwide. Primary and secondary prevention have led to better outcomes in developed countries, whereas in developing countries, cervical cancer continues to be responsible for an unjustifiably high number of fatalities. The discovery of new tumor biomarkers can lead to earlier diagnosis, better therapeutic decisions, and improved treatment methods.
View Article and Find Full Text PDFInsulin-like growth factor II mRNA binding protein 3 is highly expressed in primary diffuse large B-cell lymphoma of the CNS.
J Clin Exp Hematop
September 2024
Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Article Synopsis
- - The study investigates the use of IMP3 immunohistochemistry (IHC) as a diagnostic tool for primary diffuse large B-cell lymphoma of the central nervous system (CNS-DLBCL), which is challenging to diagnose due to limited biopsy material.
- - Results showed strong IMP3 expression in 100% of CNS-DLBCL samples, while it was also present in 88.2% of other DLBCLs, but not in inflammatory brain diseases.
- - While IMP3 IHC can help distinguish CNS-DLBCL in cases with limited tumor cells, most cases can be diagnosed without it, indicating that it serves as a supportive diagnostic technique rather than a primary one.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!